Table 2. Monoamine oxidase inhibition of pyrazolobenzothiazine-based carbothioamides 3a–o and 4a–o.

Compound	MAO-A	MAO-B
	IC50 ± SEM (μM)
3a	0.01 ± 0.0005	3.13 ± 0.14
3b	0.003 ± 0.0007	29.5 ± 4.68
3c	3.69 ± 0.04	4.15 ± 0.57
3d	1.77 ± 0.03	2.91 ± 0.04
3e	1.13 ± 0.001	0.11 ± 0.005
3f	0.01 ± 0.0005	6.11 ± 0.07
3g	4.06 ± 0.07	6.21 ± 0.09
3h	1.11 ± 0.003	2.89 ± 0.07
3i	3.49 ± 0.05	0.43 ± 0.006
3j	1.42 ± 0.004	3.83 ± 0.03
3k	0.47 ± 0.007	1.68 ± 0.005
3l	30.2 ± 5.02	41% a
3m	76.2 ± 7.31	4.72 ± 0.38
3n	64.8 ± 5.28	4.34 ± 0.06
3o	31.2 ± 4.07	36% a
4a	ND b	ND b
4b	ND b	ND b
4c	27.2 ± 3.62	2.49 ± 0.03
4d	8.18 ± 1.94	0.02 ± 0.001
4e	9.15 ± 2.04	0.75 ± 0.004
4f	65.7 ± 7.91	0.77 ± 0.005
4g	33.8 ± 4.62	0.68 ± 0.003
4h	7.73 ± 0.16	20.9 ± 2.74
4i	2.06 ± 0.01	3.27 ± 0.04
4j	0.54 ± 0.006	19% a
4k	9.02 ± 0.08	1.76 ± 0.008
4l	2.33 ± 0.03	6.99 ± 0.05
4m	10.6 ± 1.01	0.64 ± 0.007
4n	3.07 ± 0.19	2.99 ± 0.06
4o	0.97 ± 0.07	2.39 ± 0.05
Clorgyline	0.0045 ± 0.0003	61.35 ± 1.13
Deprenyl	67.25 ± 1.02	0.0196 ± 0.001

^a% inhibition at 100 μM end concentration.

^bND: not determined.